SEC Form 4 · accession 0001209191-18-002512
Corbus Pharmaceuticals Holdings, Inc. · CRBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yuval Cohen
Officer — Chief Executive Officer · Director
Period of report
Jan 4, 2018
Accepted (ET)
Jan 5, 2018 · 5:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001595097
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option(right to buy)F1 | $8.35 | Jan 4, 2018 | A | 437,500 | A | — | Jan 4, 2028 | Common Stock | 437,500 | 437,500 | D |
Explanation of responses
- F1The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on January 4, 2019, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 4, 2019.